3/3/2022

speaker
Operator
Conference Call Operator

Ladies and gentlemen, welcome to the Antares Pharma 4th Quarter and Full Year 2021 Financial and Operating Results Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions. If you would like to ask a question, please press star 1 on your telephone keypad. I would now like to hand the conference over to Tram Bui, Antares Vice President, and Corporate Communications and Investor Relations. Please go ahead.

speaker
Tram Bui
Antares Vice President, Corporate Communications and Investor Relations

thank you operator and good morning everyone earlier today we announced our fourth quarter and full year 2021 financial results and operating achievements a copy of the press release and slide presentation for today's conference call are available in the investor release relations section of the entire pharma corporate website before we begin i'd like to remind listeners that some of the statements made during this conference call will contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of board looking statements include those related to our future financial and operating results, including our expectations regarding the impact of the ongoing COVID-19 pandemic on our overall business, operating results and financial condition, our ability to achieve our 2022 revenue guidance, future revenue growth, prescription volumes, product launches, and market share for our products, and our partner products, FDA actions and potential regulatory approval for our products and for our partner products, timing and results of ongoing and future development programs and clinical trials for our products and for our partner products, future actions by our partners, and future business development efforts. These forward-looking statements are subject to certain risks and uncertainties, and actual results could differ materially. They are identified and described in today's press release in the accompanying slide presentation on slide 2 and in the company's filings with the SEC on Form 10-K and as updated in Antares' recent periodic filings on Form 10-Q and Form 8-K. Antares is providing this information as of the date of today's conference call and does not undertake any obligation to update any forward-looking statements contained in this conference call as a result of new information, future events, or circumstances after the date hereof except as required by law or otherwise. The company cautions investors not to place undue reliance on these forward-looking statements. This presentation will also include reference to non-GAAP financial measures. These measures are used by management to evaluate the operating performance of the company over time. They should not be considered in isolation or as a substitute for GAAP measures. A reconciliation of our non-GAAP measures to the nearest GAAP measures can be found in our earnings release. Joining me on the call today are Bob Apple, President and Chief Executive Officer, Fred Powell, Executive Vice President and Chief Financial Officer, Dr. Peter Richardson, Executive Vice President, Research and Development and Chief Medical Officer, and Joe Render, Senior Vice President of Commercial. Let's review the agenda for today's call on slide three. Bob will begin with a review of our overall business and accomplishments in 2021 and then hand the call over to Joe to provide an update on our commercial achievements and strategy for our proprietary portfolio. Dr. Richardson will then discuss our R&D pipeline and initiatives before handing the call back to Bob to provide a review of our customer business. Fred will then go through the detailed financials and Bob will conclude with closing comments before opening up the line to your questions, which we ask to be limited to two questions per caller. Please turn to slide four, and then I will hand the call over to Bob Apple. Bob.

speaker
Bob Apple
President and Chief Executive Officer

Thanks, John. Good morning. Thank you for your interest in our fourth quarter and full year 2021 results and operations update. We are very excited to report another record year with outstanding financial and operating results. In 2021, NTARI successfully executed on our strategic initiatives, and we believe we have built a foundation for continued growth. We believe our financial and operating results for the full year spotlight on the overall strength of the company, as well as highlight the potential future growth opportunities we have across our proprietary and partner business. For the full year, our total revenue increased 23% year-over-year to $184 million, which puts us at the midpoint of our revenue guidance range of $180 to $190 million. We also generated almost $40 million in adjusted EBITDA and substantially improved our balance sheet with almost $66 million in cash as of the end of the year. I'm extremely proud of the accomplishments we achieved across the entire organization despite another challenging year due to the ongoing pandemic. Throughout the year, our commercial team continued to build and maintain strong physician relationships that helped drive the 34% annual revenue increase in our flagship proprietary asset, Ziosted, to over $62 million. We also worked relentlessly to support the strong demand for Tevis Generic EpiPen, which contributed approximately $70 million in annual revenue. As we forged more balance between our proprietary and partner business, these two assets were foundational to our growth in 2021. We also executed on our strategic objectives to expand and streamline our proprietary portfolio focus, which supports our strong growth expectations in 2022. First, the in-licensing of Palando gives us the opportunity to compliment Zyestad with an oral formulation of testosterone, which has been tentatively approved by the FDA. We intend to leverage our expertise and success in the testosterone market support the launch of tolando and drive market share gains with our broader offering with the fda's acceptance of our nda submission resubmission for tolando we look forward to the march 28th paducah date any final fda approval we are excited to launch in the second quarter with an expanded commercial organization at the end of the year we completed the divestiture of Otrexa, which was a non-core legacy asset that we introduced back in 2013. This divestiture allows our commercial team to focus their call points with urologists and endocrinologists, while at the same time, strengthen our balance sheet. Overall, we expect our proprietary portfolio with Ziosted, Talando, and Nocturna to be core to our future growth. As we look ahead, we expect our 2022 revenue to be in the range of $200 to $220 million and does not include any unapproved products such as Tolando or Tevis Frateo. During the past year, we also made significant advancements in the development of our pipeline, particularly ATRS 1902 for adrenal crisis rescue. Completing our IMD filing in the third quarter of last year allowed the company to initiate and subsequently report positive phase one results. In addition, the FDA's recent fast track designation was further validation for the unmet need for this rescue pet for those suffering from adrenal crisis. Our advancements of 1902 highlights our commitment to our research and development as well as the opportunity to continue to leverage our platform technology with ATRS 1901 and the recent introduction of ATRS 1903. Our advancements on our internal pipeline were bolstered by the progress in our partner pipeline of products, led by the initiation of a Dorsius Phase III program for the Salada Grow Heart Attack Rescue Pen. We anticipate these internal achievements, coupled with the potential opportunities that remain with our partner business, to provide a strong foundation, which we expect we will continue to grow. As the organization continues to expand and flourish, we have built a leadership team that has cultivated a high-performing culture where our employees are critical to our ongoing success. With that, I am excited to welcome Claude Richardson, who recently joined Antares as our Senior VP of Human Resources. I look forward to leveraging his proven ability to develop and manage an HR strategy that will help drive performance and support our future growth. Let me now hand the call over to Joe to provide an overview of our commercial achievement and provide more detail on our commercial strategy for our proprietary portfolio.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-